Physician profile
Fang Wang
NPI 1689865289
$6,078.38
in general payments reported to CMS, 2019-2025
31 companies · $669 in 2025
The $669 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,055 · 2020: $311 · 2021: $1,197 · 2022: $936 · 2023: $1,080 · 2024: $830 · 2025: $669.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,579.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,579.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,946.88 | 2019-2025 | Rinvoq, Humira, Skyrizi |
| Amgen INC. | $743.39 | 2019-2025 | Enbrel, Otezla, Repatha |
| Astrazeneca Pharmaceuticals Lp | $461.59 | 2021-2025 | Breztri, Farxiga |
| Glaxosmithkline, LLC. | $405.58 | 2022-2024 | Shingrix, Trelegy Ellipta, Arexvy |
| Pfizer INC. | $379.54 | 2019-2024 | |
| Genentech USA, INC. | $302.97 | 2019-2020 | |
| Lilly USA, LLC | $207.14 | 2019-2025 | Mounjaro, Trulicity |
| Amarin Pharma, INC. | $206.51 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $172.63 | 2023-2025 | |
| Esperion Therapeutics, INC. | $150.21 | 2021 | |
| Janssen Biotech, INC. | $149.59 | 2021-2024 | Tremfya |
| Horizon Therapeutics Plc | $120.15 | 2020-2022 | |
| Radius Health, INC. | $100.45 | 2025 | Tymlos |
| Mannkind Corporation | $89.14 | 2024 | |
| Gilead Sciences, INC. | $87.91 | 2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $66.98 | 2022 | |
| Stryker Corporation | $60.35 | 2024-2025 | Dermacell, Spy-Phi System, Photonsaber F |
| Idorsia Pharmaceuticals US INC | $57.94 | 2023 | Quviviq |
| Novo Nordisk INC | $51.49 | 2021-2025 | Ozempic |
| Phathom Pharmaceuticals, INC. | $47.87 | 2024-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.85 | 2019-2022 | |
| Vbi Vaccine (Delaware) INC. | $41.30 | 2023 | Prehevbrio |
| Davol INC. | $34.21 | 2024 | Phasix Mesh |
| Valeritas, INC. | $24.56 | 2019 | |
| Novartis Pharmaceuticals Corporation | $21.31 | 2019 | |
| Si-Bone, INC. | $20.02 | 2022 | |
| Abbott Laboratories | $19.07 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.93 | 2020 | |
| Eisai INC. | $18.30 | 2021 | |
| Mallinckrodt Hospital Products INC. | $15.36 | 2020 | |
| Ibsa Pharma INC. | $11.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fang Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.